# US 5,344,393 A · Use of synthetic oxygen carriers to facilitate oxygen delivery > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,344,393 A - Document ID: US5344393A - Status: Granted - Kind: A - Application number: 07/843,518 - Filed: 1992-02-28 - Granted: 1994-09-06 - Earliest claimed: 1992-02-28 - Assignees: Alliance Pharmaceutical Corp. - Inventors: Duane J. Roth; Peter E. Keipert; Nicholas S. Faithfull; Thomas F. Zuck; Jean G. Riess - Web page: https://patentgrep.com/patent/US5344393A ## CPC - A61K 31/02: Halogenated hydrocarbons - A61K 38/42: Haemoglobins; Myoglobins - A61M 1/02: Blood transfusion apparatus (blood infusion by syringes A61M5/14) - A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) - A61M 2202/0476: Oxygenated solutions - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of removing and preferably storing a portion of the patient's blood, intravenously administering a biocompatible liquid in sufficient quantity to substantially maintain the patient's hemodynamic stability, wherein the liquid comprises an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier, after which the patient undergoes a loss of blood, and then readministering blood to the patient, preferably the stored blood. In one embodiment, the biocompatible liquid further comprises a hemodiluent and the hemodiluent is administered separately from the oxygen carrier. ## Claims ### Claim 1 A method for facilitating autologous blood use by a patient facing a loss of blood, comprising the steps of: removing and storing a portion of the patient's blood; intravenously administering a biocompatible liquid in sufficient quantity to maintain the patient's blood volume, wherein said liquid comprises an effective oxygen-delivery enhancing amount of a synthetic biocompatible oxygen carrier; having said patient undergo a loss of blood subsequent to the administration of the biocompatible liquid; administering breathing gas enriched with a concentrated of 50%-100% oxygen to said patient during said loss of blood; and readministering said stored blood to said patient. ### Claim 2 (depends on 1) The method of claim 1, wherein the biocompatible liquid further comprises a hemodiluent and wherein said hemodiluent is administered separately from said oxygen carrier. ### Claim 3 (depends on 1) The method of claim 1, wherein the oxygen carrier is derived from human, animal, plant, or recombinant hemoglobin. ### Claim 4 (depends on 1) The method of claim 1, wherein the oxygen carrier is a fluorocarbon emulsion. ### Claim 5 (depends on 2) The method of claim 2, wherein the said oxygen carrier is a fluorocarbon emulsion and the volume of said administered oxygen carrier is less than 50% of the volume of said hemodiluent. ### Claim 6 (depends on 4) The method of claim 4, wherein said fluorocarbon emulsion has a concentration of at least 40%, w/v. ### Claim 7 (depends on 6) The method of claim 6, wherein the concentration of said fluorocarbon emulsion is at least 60%, w/v. ### Claim 8 (depends on 1) The method of claim 1, wherein said hemodiluent is a crystalloid, a colloid, or a combination thereof. ### Claim 9 (depends on 1) The method of claim 1, wherein said blood loss is associated with surgery. ### Claim 10 (depends on 1) The method of claim 1, wherein said blood loss is associated with trauma. ### Claim 11 (depends on 1) The method of claim 1, wherein the amount of oxygen carrier administered is between about 0.5 and 10 g/kg, based on the body weight of the patient. ### Claim 12 (depends on 1) The method of claim 1, wherein said biocompatible liquid includes a hemodiluent. ### Claim 13 (depends on 1) The method of claim 1, wherein said quantity of biocompatible liquid is from about 75% to about 300% of the volume of blood removed in said removing step. ### Claim 14 (depends on 9) The method of claim 9, further comprising the step of administering an additional amount of a biocompatible synthetic oxygen carrier to said patient during said surgery. ### Claim 15 A method for facilitating autologous blood use by a patient facing a loss of blood during surgery, comprising the steps of: removing and storing a portion of the patient's blood; intravenously administering a hemodiluent to said patient in conjunction with the removing step in a volume at least as great as the volume of blood removed, thereby increasing the cardiac output of the patient; thereafter initiating a surgical procedure on said patient, said surgical procedure involving a loss of blood; administering an effective oxygen-delivery enhancing amount of a biocompatible synthetic oxygen carrier to said patient during said surgical procedure; and administering a breathing gas to said patient during said surgical procedure, said breathing gas being enriched with a concentration of 50%-100% oxygen. ### Claim 16 (depends on 15) The method of claim 15, wherein said synthetic oxygen carrier is a fluorocarbon emulsion and the administered volume of fluorocarbon is less than 50% of the volume of said hemodiluent. ### Claim 17 (depends on 15) The method of claim 15, further comprising the step of readministering said stored blood to said patient.